Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
June 2016
-
The future of chronic myeloid leukemia is evolving
-
Media Release
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] … -
The eye: the fastest muscle in the human body
How much do you know about eyes? Learn more about the fastest muscle in the human body.
-
Media Release
Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma
Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of… -
Media Release
Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer
The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar® + Mekinist® combination therapy was 9 months Efficacy analyses also presented for INC280 (… -
Fighting pneumonia, the biggest killer of young children
Pneumonia causes around 2 million child deaths per year globally and the burden is especially heavy in a country like Bangladesh, where a third of the population is aged 14 or below.
-
Lung Cancer: To test or not to test
For patients with lung cancer, biomarker testing may be an option.
-
Media Release
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the >… -
Your Genes, Your Melanoma
Learn about the role of precision oncology in advanced melanoma treatment.
-
In The News
Novartis Access hosts second stakeholder dialogue
The second stakeholder dialogue shared first learnings from the Kenya launch, and to continue the discussion on how to address the burden of NCDs in lower-income countries. -
Media Release
Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET)
Afinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Nonfunctional GI and lung NET are…
Pagination
- ‹ Previous page
- 1
- …
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- …
- 154
- › Next page
Test disclaimer...!!!